PRQR (ProQR Therapeutics) רווח למניה בארבעת הרבעונים האחרונים

ProQR Therapeutics N.V. (PRQR) oligonucleotide synthesis production capacities are fully utilized, while drug manufacturing is delegated to external contractors. This price chart with the -4.60 metric illustrates the dynamics of the company, which develops RNA editing methods to combat hereditary pathologies. The business relies on strong patent protection and authority in ophthalmology, where the brand's innovations offer patients with rare eye diseases a chance to restore their vision.
ProQR Therapeutics N.V. - פילוחים אנליטיים ומדדי מפתח (PRQR)

For RNA editing leader ProQR Therapeutics N.V. (PRQR), the annual percentage change in earnings per share (ttm) serves as an indicator of the commercialization efficiency of the Axiomer platform. This metric is calculated as the percentage difference between the current and previous twelve-month EPS values. It reflects the business's ability to transform technological advantages into actual net profit. Steady growth in this indicator confirms the company's financial stability against the backdrop of high R&D costs.